While the selection of amino acid insertions in human immunodeficiency virus (HIV) reverse transcriptase (RT) is a known mechanism of resistance against RT inhibitors, very few reports on the selection of insertions in the protease (PR) coding region have been published. It is still unclear whether these insertions impact protease inhibitor (PI) resistance and/or viral replication capacity. We show that the prevalence of insertions, especially between amino acids 30 to 41 of HIV type 1 (HIV-1) PR, has increased in recent years. We identified amino acid insertions at positions 33 and 35 of the PR of HIV-1-infected patients who had undergone prolonged treatment with PIs, and we characterized the contribution of these insertions to viral resistance. We prepared the corresponding mutated, recombinant PR variants with or without insertions at positions 33 and 35 and characterized them in terms of enzyme kinetics and crystal structures. We also engineered the corresponding recombinant viruses and analyzed the PR susceptibility and replication capacity by recombinant virus assay. Both in vitro methods confirmed that the amino acid insertions at positions 33 and 35 contribute to the viral resistance to most of the tested PIs. The structural analysis revealed local structural rearrangements in the flap region and in the substrate binding pockets. The enlargement of the PR substrate binding site together with impaired flap dynamics could account for the weaker inhibitor binding by the insertion mutants. Amino acid insertions in the vicinity of the binding cleft therefore represent a novel mechanism of HIV resistance development.

Gilead Sciences and IOCB Research Center Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic v v i Flemingovo 2 166 10 Praha 6 Czech Republic

Zobrazit více v PubMed

Bailey, S. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50760-763. PubMed

Betts, M. J., and M. J. Sternberg. 1999. An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng. 12271-283. PubMed

Boom, R., C. J. Sol, M. M. Salimans, C. L. Jansen, P. M. Wertheim-van Dillen, and J. van der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28495-503. PubMed PMC

Borman, A. M., S. Paulos, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77419-426. PubMed

Boucher, C. A., W. Keulen, T. van Bommel, M. Nijhuis, D. de Jong, M. D. de Jong, P. Schipper, and N. K. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 402404-2409. PubMed PMC

Brann, T. W., R. L. Dewar, M. K. Jiang, A. Shah, K. Nagashima, J. A. Metcalf, J. Falloon, H. C. Lane, and T. Imamichi. 2006. Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness. J. Virol. 806136-6145. PubMed PMC

Brynda, J., P. Rezacova, M. Fabry, M. Horejsi, R. Stouracova, M. Soucek, M. Hradilek, J. Konvalinka, and J. Sedlacek. 2004. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. Acta Crystallogr. D 601943-1948. PubMed

Cigler, P., M. Kozisek, P. Rezacova, J. Brynda, Z. Otwinowski, J. Pokorna, J. Plesek, B. Grüner, L. Doleckova-Maresova, M. Masa, J. Sedlacek, J. Bodem, H. G. Kräusslich, V. Kral, and J. Konvalinka. 2005. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. USA 10215394-15399. PubMed PMC

Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Tepplert, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374569-571. PubMed

De Clercq, E. 2007. Anti-HIV drugs. Verh. K. Acad. Geneeskd. Belg. 6981-104. PubMed

de Mendoza, C., J. Morello, P. Garcia-Gasco, S. Rodriguez-Novoa, and V. Soriano. 2007. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opin. Pharmacother. 8839-850. PubMed

Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 703763-3769. PubMed PMC

Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 602126-2132. PubMed

Gulnik, S. V., L. I. Suyorov, B. Lju, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 349282-9287. PubMed

Jones, S., and J. M. Thornton. 1996. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. USA 9313-20. PubMed PMC

Kagan, R. M., P. K. Cheung, T. K. Huard, and M. A. Lewinski. 2006. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment. Antivir. Res. 7142-52. PubMed

Kagan, R. M., M. D. Shenderovich, P. N. Heseltine, and K. Ramnarayan. 2005. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 141870-1878. PubMed PMC

Kim, E. Y., M. A. Winters, R. M. Kagan, and T. C. Merigan. 2001. Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. J. Virol. 7511227-11233. PubMed PMC

Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 854686-4690. PubMed PMC

Laskowski, R. A. 1995. SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. J. Mol. Graph 13323-328. PubMed

Maguire, M., D. Shortino, A. Klein, W. Harris, V. Manohitharajah, M. Tisdale, R. Elston, J. Yeo, S. Randall, F. Xu, H. Parker, J. May, and W. Snowden. 2002. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46731-738. PubMed PMC

Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 727632-7637. PubMed PMC

Masquelier, B., C. Droz, M. Dary, C. Perronne, V. Ferré, B. Spire, D. Descamps, F. Raffi, F. Brun-Vézinet, G. Chêne, and the APROCO/COPILOTE Study Group. 2003. R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virologic failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen. Antimicrob. Agents Chemother. 473623-3626. PubMed PMC

Masquelier, B., E. Race, C. Tamalet, D. Descamps, J. Izopet, C. Buffet-Janvresse, A. Ruffault, A. S. Mohammed, J. Cottalorda, A. Schmuck, V. Calvez, E. Dam, H. Fleury, and F. Brun-Vezinet. 2001. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 451836-1842. PubMed PMC

Minor, W., M. Cymborowski, Z. Otwinowski, and M. Chruszcz. 2006. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta Crystallogr. D 62859-866. PubMed

Moore, J. P., J. A. McKeating, R. A. Weiss, and Q. J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 2501139-1142. PubMed

Murshudov, G. N., A. A. Vagin, and E. J. Dodson. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53240-255. PubMed

Nijhuis, M., N. M. van Maarseveen, S. Lastere, P. Schipper, E. Coakley, B. Glass, M. Rovenska, D. de Jong, C. Chappey, I. W. Goedegebuure, G. Heilek-Snyder, D. Dulude, N. Cammack, L. Brakier-Gingra, J. Konvalinka, N. Parkin, H.-G. Kräusslich, F. Brun-Vezinet, and C. A. Boucher. 2007. A novel substrate based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4152-163. PubMed PMC

Nijhuis, M., R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C. A. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 132349-2359. PubMed

Paolucci, S., F. Baldanti, L. Dossena, and G. Gerna. 2006. Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility. Antivir. Res. 69181-185. PubMed

Prejdova, J., M. Soucek, and J. Konvalinka. 2004. Determining and overcoming resistance to HIV protease inhibitors. Curr. Drug Targets Infect. Disord. 4137-152. PubMed

Rhee, S. Y., W. J. Fessel, A. R. Zolopa, L. Hurley, T. Liu, J. Taylor, D. P. Nguyen, S. Slome, D. Klein, M. Horberg, J. Flamm, S. Follansbee, J. M. Schapiro, and R. W. Shafer. 2005. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J. Infect. Dis. 192456-465. PubMed PMC

Rose, R. B., C. S. Craik, and R. M. Stroud. 1998. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 372607-2621. PubMed

Strisovsky, K., U. Tessmer, J. Langner, J. Konvalinka, and H. G. Kräusslich. 2000. Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: re-thinking the “fireman's grip” hypothesis. Protein Sci. 91631-1641. PubMed PMC

Stura, E. A., and I. A. Wilson. 1991. Applications of the streak seeding technique in protein crystallization. J. Cryst. Growth 110270-282.

van Maarseveen, N. M., D. de Jong, C. A. Boucher, and M. Nijhuis. 2006. An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs. J. Acquir. Immune Defic. Syndr. 42162-168. PubMed

van Maarseveen, N. M., M. C. Huigen, D. de Jong, A. M. Smits, C. A. Boucher, and M. Nijhuis. 2006. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J. Virol. Methods 133185-194. PubMed

Vora, S., A. G. Marcelin, H. F. Gunthard, P. Flandre, H. H. Hirsch, B. Masquelier, A. Zinkernagel, G. Peytavin, V. Calvez, L. Perrin, and S. Yerly. 2006. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 2035-40. PubMed

Weber, J., J. R. Mesters, M. Lepsik, J. Prejdova, M. Svec, J. Sponarova, P. Mlcochova, K. Skalicka, K. Strisovsky, T. Uhlikova, M. Soucek, L. Machala, M. Stankova, J. Vondrasek, T. Klimkait, H.-G. Kräusslich, R. Hilgenfeld, and J. Konvalinka. 2002. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J. Mol. Biol. 324739-754. PubMed

Williams, J. W., and J. F. Morrison. 1979. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63437-467. PubMed

Winn, M. D., G. N. Murshudov, and M. Z. Papiz. 2003. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 374300-321. PubMed

Winters, M. A., R. M. Kagan, L. Kovari, P. N. Heseltine, and T. C. Merigan. 2005. Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors. Antivir. Ther. 10363-366. PubMed

Winters, M. A., and T. C. Merigan. 2005. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob. Agents Chemother. 492575-2582. PubMed PMC

Wu, T. D., C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer. 2003. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 774836-4847. PubMed PMC

Yin, P. D., D. Das, and H. Mitsuya. 2006. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance. Cell Mol. Life Sci. 631706-1724. PubMed PMC

Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 716662-6670. PubMed PMC

Structural and biochemical characterization of a novel aminopeptidase from human intestine

Inhibitor and substrate binding induced stability of HIV-1 protease against sequential dissociation and unfolding revealed by high pressure spectroscopy and kinetics

GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions

Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease

Current and Novel Inhibitors of HIV Protease

Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir